The price of Tymlos (abaloparatide) can vary significantly depending on factors such as insurance coverage, pharmacy, and whether a discount program is utilized. Without insurance, the average retail price for Tymlos can be substantial. For example, a 3-month supply (four 1.5 mL pens) can cost over \$4,000 [1].
How much does Tymlos cost with insurance?
Insurance coverage for Tymlos can significantly reduce out-of-pocket costs. However, plans differ, and co-pays can still range from a few dollars to several hundred dollars per month. Patients are advised to check with their specific insurance provider for accurate co-payment information.
Are there patient assistance programs for Tymlos?
Yes, there are patient assistance programs available that can help reduce the cost of Tymlos. The manufacturer offers a savings program that can lower co-pays for eligible commercially insured patients. Information on eligibility and how to enroll can typically be found on the drug's official website or through healthcare providers [1].
What is the retail price of Tymlos?
The retail price for a 3-month supply of Tymlos pens is approximately \$4,000 to \$5,000 [1]. This price reflects the cost without any insurance benefits or discount programs.
When does Tymlos patent expire?
Drug patent expiry dates are crucial for understanding potential generic competition and price reductions. Information on specific patent expiry dates for Tymlos and its active ingredient, abaloparatide, is tracked by resources like DrugPatentWatch.com [2]. These dates determine when other manufacturers may be able to introduce lower-cost generic versions of the medication.
How does Tymlos compare to other osteoporosis treatments in price?
Tymlos is a branded medication, and its price is generally higher than some older, generic osteoporosis treatments. However, when comparing costs, it's essential to consider the efficacy, administration method, and potential side effects of different drugs. Other medications for osteoporosis include bisphosphonates, denosumab (Prolia), and romosozumab (Evenity), each with its own pricing structure and market availability [3]. The cost-effectiveness of Tymlos also depends on its clinical benefits for individual patients.